Subgroup analyses indicated the reduced risk of the composite endpoint of 3P-MACE in patients with RA (OR = 0.64, 95% CI, 0.47 to 0.88, I2 = 0%), in patients with TNF-α treatment (OR = 0.61, 95% CI, 0.45 to 0.84, I2 = 0%), and in patients with follow-up duration more than one year (OR = 0.59, 95% CI, 0.43 to 0.80, I2 = 0%) (Table S6). Here, TNF is linked to rheumatoid arthritis.